– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan: Interim Analysis Now...
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of...
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond...
New data shows that CAR T cells engineered in vivo with VivoVec particles mediate durable antitumor activity Potent and durable...
Company announcement No. 51 / 2022 Zealand Pharma Announces Financial Results for the First Nine Months of 2022 Copenhagen, Denmark...
New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 (GLOBE...
Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy...
- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class...
Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1...
Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line...
Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for...
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
- Median Overall Survival for GPS Combination (GPS in Combination with Keytruda) was 18.4 Months Compared to 13.8 months in...
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid...
Reports progress towards global supply chain development Ended the third quarter of 2022 with cash, cash equivalents and marketable securities...
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating...
– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology...
Intermountain Healthcare caregiver visits with a patient Intermountain researchers examined 33,088 people who tested positive for COVID-19 between March 14,...
Company plans to realign in an effort to improve efficiencies, while lowering its capital requirements to invest in innovation; estimated...
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today...